Ra Capital Management, L.p. sold $5.5M of SION
director, owner at Sionna Therapeutics, Inc.. 136,351 shares at an average of $40.34, traded Nov 17, 2025, filed Nov 19, 2025.
Score components
- +15RoleDirector
- +25Trade size$5.5M at market
- 0Share of holdings soldSold 2.0% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000527, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -2,182 | $40.20 | $88k | 6,903,443 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -17,913 | $40.20 | $720k | 698,075 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -11,626 | $40.20 | $467k | 2,229,082 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -13,734 | $40.20 | $552k | 195,657 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -1,701 | $41.05 | $70k | 6,901,742 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -13,964 | $41.05 | $573k | 684,111 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -9,063 | $41.05 | $372k | 2,220,019 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -10,707 | $41.05 | $440k | 184,950 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -53 | $42.10 | $2,231 | 6,901,689 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -433 | $42.10 | $18k | 683,678 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -280 | $42.10 | $12k | 2,219,739 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -331 | $42.10 | $14k | 184,619 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -332 | $39.57 | $13k | 6,901,357 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -2,728 | $39.57 | $108k | 680,950 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -1,770 | $39.57 | $70k | 2,217,969 | Nov 19, 2025 |
| Nov 18, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -2,092 | $39.57 | $83k | 182,527 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -2,276 | $40.01 | $91k | 6,899,081 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -18,684 | $40.01 | $748k | 662,266 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -12,126 | $40.01 | $485k | 2,205,843 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -14,325 | $40.01 | $573k | 168,202 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -2 | $40.61 | $81 | 6,899,079 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -12 | $40.61 | $487 | 662,254 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -8 | $40.61 | $325 | 2,205,835 | Nov 19, 2025 |
| Nov 19, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -9 | $40.61 | $365 | 168,193 | Nov 19, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 15Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $347k 10,250 shares | -100% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $1.4M 30,953 shares | -1% | |
| 45Moderate | Sionna Therapeutics, Inc. | Tpg Gp A, LLC owner | $10M 250,000 shares | -4% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $1.5M 33,356 shares | -1% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $1.5M 33,356 shares | -1% | |
| 19Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $83k 1,875 shares | -0% | |
| 19Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $83k 1,875 shares | -0% | |
| 31Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $415k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4.8M 108,073 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.